{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:27:58Z","timestamp":1786753678682,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Probes"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.mcp.2026.102080","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:05:35Z","timestamp":1785251135000},"page":"102080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inhibitory effects of hinokiflavone on human liver cytochrome P450 enzymes"],"prefix":"10.1016","volume":"89","author":[{"given":"Ning","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9554-3279","authenticated-orcid":false,"given":"Deyou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.mcp.2026.102080_bib1","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1039\/b505362p","article-title":"Cytochrome P450s: creating novel ligand sets","author":"Seward","year":"2005","journal-title":"Dalton Trans."},{"issue":"6006","key":"10.1016\/j.mcp.2026.102080_bib2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1126\/science.1193478","article-title":"Cytochrome P450 compound I: capture, characterization, and C-H bond activation kinetics","volume":"330","author":"Rittle","year":"2010","journal-title":"Science (New York, NY)"},{"issue":"16","key":"10.1016\/j.mcp.2026.102080_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26167797","article-title":"Natural polymorphic variants in the CYP450 superfamily: a review of potential structural mechanisms and functional consequences","volume":"26","author":"Prost","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/biom14010099","article-title":"A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment","volume":"14","author":"Lee","year":"2024","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.mcp.2026.102080_bib5","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/03602532.2025.2603936","article-title":"Role of herbal extracts in modulating drug metabolism: implications for pharmacokinetics, enzyme regulation, and therapeutic outcome","volume":"58","author":"Khan","year":"2026","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.mcp.2026.102080_bib7","article-title":"Drug repurposing in traditional Chinese medicine: from empirical wisdom to modern therapeutic strategies","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"14","key":"10.1016\/j.mcp.2026.102080_bib8","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1111\/jcmm.15474","article-title":"Hinokiflavone induces apoptosis via activating mitochondrial ROS\/JNK\/caspase pathway and inhibiting NF-\u03baB activity in hepatocellular carcinoma","volume":"24","author":"Mu","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.mcp.2026.102080_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122968","article-title":"Hinokiflavone exerts dual regulation on apoptosis and pyroptosis via the SIX4\/Stat3\/Akt pathway to alleviate APAP-induced liver injury","volume":"354","author":"Liu","year":"2024","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cells15010017","article-title":"Hinokiflavone as a potential antitumor agent: from pharmacology to pharmaceutics","volume":"15","author":"Liu","year":"2025","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.mcp.2026.102080_bib11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s12032-025-02800-7","article-title":"In silico investigation of Toxicodendron succedaneum phytochemicals as extracellular signal-regulated kinase 2 inhibitors for non-small cell lung cancer therapy","volume":"42","author":"Ahmed","year":"2025","journal-title":"Medical oncology (Northwood, London, England)"},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/10717544.2020.1748760","article-title":"Preparation and antitumor evaluation of hinokiflavone hybrid micelles with mitochondria targeted for lung adenocarcinoma treatment","volume":"27","author":"Chen","year":"2020","journal-title":"Drug Deliv."},{"issue":"5","key":"10.1016\/j.mcp.2026.102080_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70002","article-title":"Probe substrates assay estimates the effect of polyphyllin H on the activity of cytochrome P450 enzymes in human liver microsomes","volume":"12","author":"Wang","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"issue":"8","key":"10.1016\/j.mcp.2026.102080_bib14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/00498254.2020.1727062","article-title":"In vitro effect of pachymic acid on the activity of Cytochrome P450 enzymes","volume":"50","author":"Ding","year":"2020","journal-title":"Xenobiotica; the fate of foreign compounds in biological systems"},{"issue":"7","key":"10.1016\/j.mcp.2026.102080_bib15","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1021\/acs.chemrestox.1c00178","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 and 3A5 by the fibroblast growth factor receptor inhibitor erdafitinib","volume":"34","author":"Tang","year":"2021","journal-title":"Chem. Res. Toxicol."},{"issue":"4","key":"10.1016\/j.mcp.2026.102080_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1124\/molpharm.120.000086","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by benzbromarone","volume":"99","author":"Tang","year":"2021","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12906-021-03397-w","article-title":"In vitro inhibitory effect of obtusofolin on the activity of CYP3A4, 2C9, and 2E1","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Complement. Med. Ther."},{"issue":"2","key":"10.1016\/j.mcp.2026.102080_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147183","article-title":"Screening of drug metabolizing enzymes for the ginsenoside compound K in vitro: an efficient anti-cancer substance originating from Panax ginseng","volume":"11","author":"Xiao","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mcp.2026.102080_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3821","article-title":"Development and validation of an LC-MS\/MS method for the determination of hinokiflavone in rat plasma and its application to a pharmacokinetic study","volume":"31","author":"Yin","year":"2017","journal-title":"Biomed. Chromatogr. : BMC (Biomed. Chromatogr.)"},{"issue":"8","key":"10.1016\/j.mcp.2026.102080_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00240-22","article-title":"Hinokiflavone attenuates the virulence of methicillin-resistant Staphylococcus aureus by targeting caseinolytic protease P","volume":"66","author":"Kong","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-06543-3","article-title":"Hinokiflavone is a novel CK2 inhibitor promoting apoptosis and synergizing with chemotherapeutic agents in cisplatin resistant bladder cancer cells","volume":"15","author":"Hsieh","year":"2025","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.mcp.2026.102080_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cbf.3443","article-title":"Hinokiflavone induces apoptosis and inhibits migration of breast cancer cells via EMT signalling pathway","volume":"38","author":"Huang","year":"2020","journal-title":"Cell Biochem. Funct."},{"issue":"5","key":"10.1016\/j.mcp.2026.102080_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1208\/s12248-025-01114-w","article-title":"Optimization of in vitro CYP3A4 TDI assay conditions and use of derived parameters for clinical DDI risk assessment using static and dynamic models","volume":"27","author":"Pugliano","year":"2025","journal-title":"AAPS J."},{"issue":"3","key":"10.1016\/j.mcp.2026.102080_bib24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00204-021-03218-6","article-title":"In vitro metabolism of helenalin and its inhibitory effect on human cytochrome P450 activity","volume":"96","author":"\u0160adibolov\u00e1","year":"2022","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12906-022-03671-5","article-title":"Human liver microsomes study on the inhibitory effect of plantainoside D on the activity of cytochrome P450 activity","volume":"22","author":"Zhou","year":"2022","journal-title":"BMC Complement. Med. Ther."},{"issue":"23","key":"10.1016\/j.mcp.2026.102080_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.mcp.2026.102080_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr. Drug Metabol."},{"issue":"12","key":"10.1016\/j.mcp.2026.102080_bib28","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1124\/dmd.110.034140","article-title":"CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs","volume":"38","author":"Maekawa","year":"2010","journal-title":"Drug Metabol. Dispos.: the biological fate of chemicals"},{"issue":"12","key":"10.1016\/j.mcp.2026.102080_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14121121","article-title":"The future of pharmacogenomics: integrating epigenetics, nutrigenomics, and beyond","volume":"14","author":"Shaman","year":"2024","journal-title":"J. Personalized Med."},{"issue":"5","key":"10.1016\/j.mcp.2026.102080_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1124\/dmd.122.001131","article-title":"Activation\/Inactivation of anticancer drugs by CYP3A4: influencing factors for personalized cancer therapy","volume":"51","author":"Wang","year":"2023","journal-title":"Drug Metabol. Dispos.: the biological fate of chemicals"},{"issue":"10","key":"10.1016\/j.mcp.2026.102080_bib31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S1470-2045(05)70388-0","article-title":"Modulation of cytochrome P450 activity: implications for cancer therapy","volume":"6","author":"Scripture","year":"2005","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.mcp.2026.102080_bib32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256440","article-title":"Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals","volume":"10","author":"Garc\u00eda-Mart\u00edn","year":"2006","journal-title":"Mol. Diagn. Ther."},{"issue":"5","key":"10.1016\/j.mcp.2026.102080_bib34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/092986711794480131","article-title":"Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development","volume":"18","author":"He","year":"2011","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.mcp.2026.102080_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FPC.0b013e32834d4962","article-title":"PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19","volume":"22","author":"Scott","year":"2012","journal-title":"Pharmacogenet. Genom."},{"issue":"11","key":"10.1016\/j.mcp.2026.102080_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/biom9110655","article-title":"Interactions of 7,8-Dihydroxyflavone with Serum Albumin as well as with CYP2C9, CYP2C19, CYP3A4, and Xanthine Oxidase Biotransformation Enzymes","volume":"9","author":"Flisz\u00e1r-Ny\u00fal","year":"2019","journal-title":"Biomolecules"},{"issue":"18","key":"10.1016\/j.mcp.2026.102080_bib37","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1157\/13088772","article-title":"[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases]","volume":"126","author":"Alonso-Navarro","year":"2006","journal-title":"Med. Cl\u00ednica"},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib38","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/13880209.2021.1917630","article-title":"Pogostone inhibits the activity of CYP3A4, 2C9, and 2E1 in vitro","volume":"59","author":"Zhang","year":"2021","journal-title":"Pharm. Biol."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib39","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/13880209.2020.1835996","article-title":"Anemarsaponin BII inhibits the activity of CYP3A4, 2D6, and 2E1 with human liver microsomes","volume":"58","author":"Wang","year":"2020","journal-title":"Pharm. Biol."},{"issue":"9","key":"10.1016\/j.mcp.2026.102080_bib40","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.2042-7158.1998.tb06914.x","article-title":"Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A","volume":"50","author":"von Moltke","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.fct.2009.10.041","article-title":"Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity","volume":"48","author":"Kimura","year":"2010","journal-title":"Food Chem. Toxicol. : an international journal published for the British Industrial Biological Research Association"},{"key":"10.1016\/j.mcp.2026.102080_bib42","first-page":"131","article-title":"Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology","volume":"95","author":"Leow","year":"2022","journal-title":"Advances in pharmacology (San Diego, Calif)"},{"issue":"9","key":"10.1016\/j.mcp.2026.102080_bib43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/00498254.2024.2395557","article-title":"Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy","volume":"54","author":"Tan","year":"2024","journal-title":"Xenobiotica; the fate of foreign compounds in biological systems"},{"issue":"12","key":"10.1016\/j.mcp.2026.102080_bib44","doi-asserted-by":"crossref","first-page":"745","DOI":"10.5414\/CP203896","article-title":"Time-dependent inhibition of CYP3A4-mediated midazolam metabolism by macrolide antibiotics in CYP3A4 genetic variants: Comparison with testosterone metabolism","volume":"59","author":"Akiyoshi","year":"2021","journal-title":"Int. J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib45","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1124\/dmd.108.022178","article-title":"Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metabol. Dispos.: the biological fate of chemicals"},{"issue":"7","key":"10.1016\/j.mcp.2026.102080_bib46","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1124\/dmd.111.038505","article-title":"Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction","volume":"39","author":"Foti","year":"2011","journal-title":"Drug Metabol. Dispos.: the biological fate of chemicals"},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/03602532.2014.1003648","article-title":"Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib","volume":"47","author":"Ho","year":"2015","journal-title":"Drug Metab. Rev."},{"issue":"2","key":"10.1016\/j.mcp.2026.102080_bib48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metabol. Dispos.: the biological fate of chemicals"},{"issue":"3","key":"10.1016\/j.mcp.2026.102080_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13030655","article-title":"How plant polyhydroxy flavonoids can hinder the metabolism of cytochrome 3A4","volume":"13","author":"Vieira","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.mcp.2026.102080_bib50","article-title":"Potent inhibition of human cytochrome P450 3A4 by biflavone components from Ginkgo Biloba and Selaginella Tamariscina","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.mcp.2026.102080_bib51","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13659-021-00298-w","article-title":"Hinokiflavone and related C-O-C-Type biflavonoids as anti-cancer compounds: properties and mechanism of action","volume":"11","author":"Goossens","year":"2021","journal-title":"Nat. Prod. Bioprospect."},{"issue":"10","key":"10.1016\/j.mcp.2026.102080_bib53","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1124\/dmd.121.000497","article-title":"Static and dynamic projections of drug-drug interactions caused by cytochrome P450 3A time-dependent inhibitors measured in human liver microsomes and hepatocytes","volume":"49","author":"Tseng","year":"2021","journal-title":"Drug Metabol. Dispos.: the biological fate of chemicals"},{"issue":"6","key":"10.1016\/j.mcp.2026.102080_bib54","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1208\/s12248-016-9962-6","article-title":"Challenges and opportunities with Non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-Glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance","volume":"18","author":"Argikar","year":"2016","journal-title":"AAPS J."},{"issue":"2\u20133","key":"10.1016\/j.mcp.2026.102080_bib55","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.toxlet.2009.09.002","article-title":"CYP1A1 and CYP3A4 modulation by dietary flavonoids in human intestinal Caco-2 cells","volume":"191","author":"Sergent","year":"2009","journal-title":"Toxicol. Lett."},{"issue":"12","key":"10.1016\/j.mcp.2026.102080_bib56","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metabol. Dispos.: the biological fate of chemicals"},{"issue":"9","key":"10.1016\/j.mcp.2026.102080_bib57","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1124\/dmd.112.046599","article-title":"Commentary: nonspecific protein binding versus membrane partitioning: it is not just semantics","volume":"40","author":"Nagar","year":"2012","journal-title":"Drug Metabol. Dispos.: the biological fate of chemicals"},{"issue":"8","key":"10.1016\/j.mcp.2026.102080_bib58","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.1007\/s00210-025-03856-y","article-title":"Inhibitory effects of cornuside on human liver cytochrome P450 enzymes","volume":"398","author":"Yang","year":"2025","journal-title":"N. Schmied. Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13318-016-0323-8","article-title":"Inhibitory effects of triptolide on human liver cytochrome P450 enzymes and P-Glycoprotein","volume":"42","author":"Zhang","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.mcp.2026.102080_bib60","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/13880209.2020.1741650","article-title":"In vitro inhibitory effects of cepharanthine on human liver cytochrome P450 enzymes","volume":"58","author":"Zhang","year":"2020","journal-title":"Pharm. Biol."}],"container-title":["Molecular and Cellular Probes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850826000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850826000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:56:01Z","timestamp":1786751761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890850826000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":59,"alternative-id":["S0890850826000204"],"URL":"https:\/\/doi.org\/10.1016\/j.mcp.2026.102080","relation":{},"ISSN":["0890-8508"],"issn-type":[{"value":"0890-8508","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effects of hinokiflavone on human liver cytochrome P450 enzymes","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Probes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcp.2026.102080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102080"}}